Angiopoietin/tie-2 as mediators of angiogenesis: a role in congestive heart failure?

AY Chong, Graham Caine, Gregory Lip

Research output: Contribution to journalArticle

21 Citations (Scopus)


Angiogenic factors, in particular vascular endothelial growth factor (VEGF) and the angiopoietins, Ang-1 and -2, have recently generated significant interest, especially in oncology. The process of angiogenesis is also thought to occur in response to ischaemic conditions, which lie at the core of cardiovascular disease states such as coronary artery disease and congestive heart failure. However, current data do not conclusively show evidence of angiogenesis per se in these conditions, despite (for example) the presence of high levels of VEGF and Ang-2. High levels of these angiogenic factors in heart disease also have not translated into clinically significant new vessel formation, as in accelerated cancer growth or proliferative retinopathy. Indeed, we would hypothesize that these angiogenic markers--especially the angiopoietins--do not necessarily translate into new vessel formation in congestive heart failure (CHF), but may well reflect disturbances of endothelial integrity in CHF.
Original languageEnglish
Pages (from-to)9-13
Number of pages5
JournalEuropean journal of clinical investigation
Issue number1
Publication statusPublished - 1 Jan 2004


  • angiopoietin
  • vascular endothelial growth factor
  • angiogenesis
  • congestive heart failure


Dive into the research topics of 'Angiopoietin/tie-2 as mediators of angiogenesis: a role in congestive heart failure?'. Together they form a unique fingerprint.

Cite this